Myriad Genetics (MYGN) Misses Q1 EPS by 3c
More News related to MYGN
- Myriad Genetics to Present at the 21st Annual Piper Jaffray Health Care Conference
- Morgan Joseph Upgrades Myriad Genetics (MYGN) to Hold; Expect Positive Sales
- Myriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Myriad Genetics (MYGN) Misses Q1 EPS by 3c
More News related to Earnings
- Peet's (PEET) Moving Even Lower as Cowen Issues Mid-Day Downgrade
- RBC Downgrades Cephalon (CEPH) Following Cinquil Trial Results; Sees 'Little Momentum' Behind the Stock
- BMO Capital Downgrades Terra Industries (TRA) to Market Perform
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Sterne Agee Downgrades Shoe Apparel Stores FINL & FL
Myriad Genetics (NASDAQ: MYGN) reports Q1 EPS of $0.31, 3 cents below the analyst estimate of $0.34.
Related Categories
EarningsStocks Mentioned
+0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
